Angel Biotechnology losses widen

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Pre-tax loss widened to £2.86m for the six month period ended September 30th 2012 most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. Angel posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.